Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/24/2026

1. INTC
2. DECK
3. INFY
4. AMD
5. UNP
6. RNG
7. URI
8. DGX
9. ACI
10. EW

Go back to Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel
(NASDAQ: LABT) Delayed: 3.06 --0 (-0%)
Previous Close $3.06    52 Week High $ 
Open $3.06    52 Week Low $ 
Day High $3.06    P/E N/A 
Day Low $3.06    EPS $ 
Volume 23,062